Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025)
Adma Biologics' (ADMA) quarterly Other Non-Current Liabilities came in at $90000.0 in Q3 2025, down 76.0% YoY from $375000.0 in Q3 2024, and up 4400.0% on a QoQ basis from $2000.0 in Q2 2025.
Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Other Non-Current Liabilities data on file, last reported at $90000.0 in Q3 2025.
- Quarterly Other Non-Current Liabilities fell 76.0% year-over-year to $90000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $90000.0 (down 76.0% YoY) and the FY2024 annual result came in at $360000.0, down 14.08% from the prior year.
- Other Non-Current Liabilities rose to $90000.0 in Q3 2025, from $2000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $449513.0 in Q2 2023 to a low of $2000.0 in Q1 2025.
- A 5-year average of $286617.5 and a median of $362179.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 934.28% — and 2025, when it slumped 99.51%.
- Tracing ADMA's Other Non-Current Liabilities over 5 years: stood at $397351.0 in 2021, then dropped by 11.92% to $350000.0 in 2022, then climbed by 19.71% to $419000.0 in 2023, then slipped by 14.08% to $360000.0 in 2024, then slumped by 75.0% to $90000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $90000.0 (Q3 2025), $2000.0 (Q2 2025), and $2000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 390,000.00 |
| Mar 31, 2024 | 405,000.00 |
| Dec 31, 2023 | 419,000.00 |
| Sep 30, 2023 | 434,647.00 |
| Jun 30, 2023 | 449,513.00 |
| Mar 31, 2023 | 338,731.00 |
| Dec 31, 2022 | 350,000.00 |
| Sep 30, 2022 | 362,179.00 |
| Jun 30, 2022 | 373,903.00 |
| Mar 31, 2022 | 385,628.00 |
| Dec 31, 2021 | 397,351.00 |
| Sep 30, 2021 | 232,665.00 |
| Jun 30, 2021 | 36,151.00 |
| Mar 31, 2021 | 41,965.00 |
| Dec 31, 2020 | 54,886.00 |